3-amino-6-cyclopropyl-4-(4-methoxyphenyl)thieno[2,3-b]pyridine-2-carboxylic acid amide | 314035-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-amino-6-cyclopropyl-4-(4-methoxyphenyl)thieno[2,3-b]pyridine-2-carboxylic acid amide
• 英文别名: 3-Amino-6-cyclopropyl-4-(4-methoxyphenyl)thieno[2,3-b]pyridine-2-carboxamide
• CAS: 314035-54-6
• 化学式: C₁₈H₁₇N₃O₂S
• 分子量: 339.418
• InChiKey: DEMDJSAVMFQUNL-UHFFFAOYSA-N

物化性质

• 沸点：
  613.1±55.0 °C(Predicted)
• 密度：
  1.388±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-Cyclopropyl-4-(4-methoxyphenyl)-2-thioxo-1,2-dihydropyridine-3-carbonitrile 、 氯乙酰胺 以72%的产率得到3-amino-6-cyclopropyl-4-(4-methoxyphenyl)thieno[2,3-b]pyridine-2-carboxylic acid amide
  参考文献：
  名称：

  Hit identification of FGFR1 inhibitors using receptor-based virtual screening

  摘要：

  DOI：

  10.7124/bc.00099f

文献信息

• [EN] THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS<br/>[FR] DÉRIVÉS DE THIÉNOPYRIDINE POUR LE TRAITEMENT ET LA PRÉVENTION D'INFECTIONS PAR LE VIRUS DE LA DENGUE
  申请人：SIGA TECHNOLOGIES INC

  公开号：WO2010099166A1

  公开（公告）日：2010-09-02

  Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

  本发明公开了用于治疗病毒感染的方法和药物组合物，通过给予治疗有效量的特定噻吩吡啶衍生物化合物来实现。还公开了使用这些化合物和药物组合物的方法。具体公开了治疗和预防由黄病毒等病毒引起的感染，包括但不限于登革病毒、西尼罗河病毒、黄热病病毒、日本脑炎病毒和蜱传脑炎病毒。
• COMPOUNDS AND METHODS FOR TREATING HIV INFECTION
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20180015077A1

  公开（公告）日：2018-01-18

  Provided herein, inter alia, are methods and compounds for treating an HIV infection.

  本文提供了用于治疗HIV感染的方法和化合物，其中包括。
• Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
  申请人：Byrd Chelsea M.

  公开号：US20120022046A1

  公开（公告）日：2012-01-26

  Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

  本发明揭示了通过以治疗有效量的某些噻唑吡啶衍生物化合物进行给药来治疗病毒感染的方法和制药组合物。本发明还揭示了使用这些化合物和制药组合物的方法。具体地，本发明揭示了治疗和预防由黄热病毒、日本脑炎病毒、西尼罗河病毒、登革热病毒和蜱传脑炎病毒等引起的病毒感染的方法。
• THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS
  申请人：Siga Technologies, Inc.

  公开号：US20160152635A1

  公开（公告）日：2016-06-02

  Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

  本发明公开了通过以治疗有效剂量给予某些噻唑吡啶衍生物化合物来治疗病毒感染的方法和制药组合物。本发明还公开了使用这些化合物和其制药组合物的方法。具体而言，本发明公开了治疗和预防由黄热病毒、日本脑炎病毒、蜱传脑炎病毒等引起的病毒感染的方法，但不限于此。
• COMPOUNDS FOR TREATMENT OF HYPOPROLIFERATIVE DISORDERS
  申请人：LU LICENSE AB

  公开号：US20190111034A1

  公开（公告）日：2019-04-18

  The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterized by reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.